ArticleMissouri medicine
Article in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) replicates via reverse transcription, a reaction catalyzed by the HBV polymerase (P) protein. P is a multidomain protein consists of terminal protein, spacer, reverse transcriptase, and ribonuclease H domains. We used a predicted structural model of HBV P and computationally identified potential non-nucleos(t)ide reverse transcriptase inhibitor (NNRTI) sites. Out of the three potential NNRTI sites, we selected Site 3 for virtual high throughput screening of 837,000 virtual compounds. We selected 53 compounds considering their docking scores, ligand uniqueness, stability and rigidity for screening in HBV replication inhibition assay, but all of them failed to suppress the HBV reverse transcription. Molecular dynamic simulations showed that Site 3 binding pocket is not conformationally stable even after binding of the ligand. This study indicates that additional potential NNRTI sites should be explored, and that rigorous molecular dynamic simulations studies should be performed before virtual compound screening.
Indexed as
Identifiers
42125278PMC13160468What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.